SCHEMBL10134799

SCHEMBL10134799

CN1CCN(c2cccc(Nc3cncc(C(=O)Nc4ccccc4)n3)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
HTR1D P28221 1/20 0.48
HTR1B P28222 1/20 0.48
HTR2A P28223 1/20 0.48
KDM1A O60341 1/20 0.46
RCOR1 Q9UKL0 1/20 0.46
JAK2 O60674 1/20 0.46
JAK3 P52333 1/20 0.46
PTK2 Q05397 1/20 0.46
FLT3 P36888 3/20 0.46
CCNT1 O60563 2/20 0.46
CDK9 P50750 2/20 0.46
CDK6 Q00534 2/20 0.46
CDK4 P11802 1/20 0.46
CCND1 P24385 1/20 0.46
CDK11A Q9UQ88 1/20 0.46
LCK P06239 1/20 0.46
MAPK14 Q16539 1/20 0.46
BRD4 O60885 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560696 0.81 ATR (0.58) KDM1ARCOR1CCNT1CDK9CDK6
SCHEMBL10134797 0.78 CDK2 (0.57) NPC1RAB9ACNR1
SCHEMBL10134808 0.77 NPC1 (0.51) NPC1RAB9AKDR
SCHEMBL10134816 0.74 JAK2 (0.53) NPC1RAB9AJAK2GSK3BCNR1
SCHEMBL10134810 0.73 RAB9A (0.56) NPC1RAB9AIRAK4GSK3B
SCHEMBL28000258 0.72 HTR2A (0.64) NPC1RAB9AHTR1DHTR1BHTR2A
SCHEMBL16489056 0.71 ATR (0.68) NPC1RAB9AIRAK4
SCHEMBL30469240 0.71 CNR1 (0.79) NPC1RAB9AHTR1DHTR1BHTR2A
SCHEMBL20557362 0.71 CNR1 (0.79) NPC1RAB9AHTR1DHTR1BHTR2A
SCHEMBL16420777 0.71 ATR (0.69) GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 NPC1 4143/4885RAB9A 3156/4885HTR1D 4701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.